HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a $32 price target.
March 04, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Verona Pharma with a $32 price target.
The reiteration of a Buy rating and maintenance of a $32 price target by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Verona Pharma. This endorsement likely boosts investor confidence in VRNA's potential, suggesting a bullish outlook for the stock in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100